Search

Your search keyword '"Macchini, M."' showing total 8 results
Start Over Author "Macchini, M." Journal esmo open
8 results on '"Macchini, M."'

1. Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI)

Author

Reni, M., Milella, M., Bergamo, F., Di Marco, M., Giommoni, E., Cardellino, G.G., Cavanna, L., Bonomi, M., Zustovich, F., Bozzarelli, S., Salmaso, F., Spada, M., Orsi, G., Macchini, M., Insolda, J., Procaccio, L., Santoni, A., De Simone, I., Caldirola, L., Galli, F., and Pinto, C.

Published
2025
Full Text
View/download PDF

2. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Author

Reni, Michele, Macchini, Marina, Orsi, Giulia, Peretti, Umberto, Valente, Mariamaddalena, Giommoni, Elisa, Antonuzzo, Lorenzo, Di Costanzo, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Lonardi, Sara, Buggin, Federica, Milella, Michele, Palmerio, Silvia, Cavanna, Luigi, Di Nunzio, Camilla, Di Marco, Maria Cristina, Grassi, Elisa, Spada, Massimiliano, Messina, Marco, Cordio, Stefano, Avola, Francesco, Aprile, Giuseppe, Pagano, Salvatore, Simionato, Francesca, Cardellino, Giovanni Gerardo, Majer, Federica, Maiello, Evaristo, Latiano, Tiziana Pia, Chiarazzo, Cinzia, Artioli, Fabrizio, Razzini, Giorgia, Pasqualini, Antonella, Ghidini, Michele, Binda, Elisa, Lazzarelli, Silvia, Bozzarelli, Silvia, Sala, Simona, Luppi, Gabriele, Pettorelli, Elisa, Spallanzani, Andrea, Vicario, Giovanni, Salmaso, Flavia, Basso, Marco, Silvestris, Nicola, Del Curatolo, Sabina, Zustovich, Fable, Bongiovanni, Francesca, Longobardi, Ciro, Sandi, Ilenia, Fontanella, Caterina, Montelatici, Silvia, Giordano, Monica, Luchena, Giovanna, Gilardoni, Micol, Tamburini, Emiliano, Rudnas, Britt, Venturini, Barbara, Merelli, Barbara, Negrini, Giorgia, Vici, Elio Maria, Marabese, Alessandra, Garetto, Cristina, Curcio, Paola, Cinieri, Saverio, Cinefra, Margherita, Ferrara, Pasqualinda, Cantore, Maurizio, Morselli, Patrizia, Fumi, Guglielmo, Isidori, Agnese, Ciccarese, Giovanni, Paolo Frassineti, Giovanni Luca, Pagan, Flavia, Vaccaro, Vanja, Spoto, Chiara, Ferrara, Marianna, Garufi, Carlo, Caporale, Marta, Vasile, Enrico, Salani, Francesca, Barone, Elisa, Berardi, Rossana, Onofri, Azzurra, Ballatore, Zelmira, Lucarelli, Alessandra, Barucca, Alessandra, Pancotti, Amedeo, Scipioni, Teresa, Bencardino, Katia, Marrapese, Giovanna, Idotta, Laura, Petrelli, Fausto, Lonati, Veronica, Ceribelli, Anna, Giuli, Angelo, Zannori, Cristina, Bassanelli, Maria, Mambrini, Andrea, Ginocchi, Laura, Orlandi, Massimo, Celio, Luigi, Niger, Monica, Biamonte, Lavinia, Tamberi, Stefano, Piancastelli, Alessandra, Papiani, Giorgio, Valli, Irene, Allione, Paolo, Boe, Maria Giovanna, Scartozzi, Mario, Lai, Eleonora, Pireddu, Annagrazia, Ziranu, Pina, Demurtas, Laura, Puzzoni, Marco, Mariani, Stefano, Pretta, Andrea, Liscia, Nicole, Savastano, Clementina, Malaspina, Valentina, Tonini, Giuseppe, Grassani, Teresa, Barco, Barbara, Pierosandro, Tagliaferri, Ciliberto, Domenico, Ierardi, Antonella, Calandruccio, Natale Daniele, Minotti, Vincenzo, Matocci, Roberta, Torri, Valter, Porcu, Luca, Rulli, Erica, De Simone, Irene, Carlucci, Luciano, Rulli, Eliana, Poli, Davide, Tonto, Paola, Scellato, Francesca, Pinto, Carmine, Reni, M., Giommoni, E., Bergamo, F., Milella, M., Cavanna, L., Di Marco, M.C., Spada, M., Cordio, S., Aprile, G., Cardellino, G.G., Maiello, E., Bernardini, I., Ghidini, M., Bozzarelli, S., Macchini, M., Orsi, G., De Simone, I., Rulli, Er., Porcu, L., Torri, V., and Pinto, C.

Published
2023
Full Text
View/download PDF

3. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

Author

Ochsenreither, S., Fiedler, W.M., Conte, G.D., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., and Garralda, E.

Published
2022
Full Text
View/download PDF

4. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey

Author

Orsi, G., Di Marco, M., Cavaliere, A., Niger, M., Bozzarelli, S., Giordano, G., Noventa, S., Rapposelli, I.G., Garajova, I., Tortora, G., Rodriquenz, M.G., Bittoni, A., Penzo, E., De Lorenzo, S., Peretti, U., Paratore, C., Bernardini, I., Mosconi, S., Spallanzani, A., Macchini, M., Tamburini, E., Bencardino, K., Giommoni, E., Scartozzi, M., Forti, L., Valente, M.M., Militello, A.M., Cascinu, S., Milella, M., and Reni, M.

Published
2021
Full Text
View/download PDF

5. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort

Author

Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Di Marco, M.C., Rodriquenz, M.G., Centonze, F., Rapposelli, I.G., Giordano, G., De Vita, F., Stuppia, L., Avallone, A., Ratti, M., Paratore, C., Forti, L.G., Orsi, G., Valente, M.M., Gaule, M., Macchini, M., Carrera, P., Calzavara, S., Simbolo, M., Melisi, D., De Braud, F., Salvatore, L., De Lorenzo, S., Chiarazzo, C., Falconi, M., Cascinu, S., Milella, M., and Reni, M.

Published
2021
Full Text
View/download PDF

6. Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447]

Author

Ochsenreither, S., Fiedler, W.M., Del Conte, G., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., and Garralda, A.

Published
2022
Full Text
View/download PDF

7. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort

Author

Michele Reni, M. Macchini, Maria Grazia Rodriquenz, F. Centonze, G. Tortora, I.G. Rapposelli, S. De Lorenzo, Michele Simbolo, Paola Carrera, A. Avallone, F. De Vita, S. Calzavara, C. Chiarazzo, Marina Gaule, Giulia Orsi, Alessandro Cavaliere, Margherita Ratti, L. Stuppia, M. Di Marco, C. Paratore, Michele Milella, F. de Braud, Monica Niger, Lisa Salvatore, Davide Melisi, Stefano Cascinu, L.G. Forti, G. Giordano, M.M. Valente, Massimo Falconi, U. Peretti, U. Peretti, A. Cavaliere, M. Niger, G. Tortora, M. C. Di Marco, M. G. Rodriquenz, F. Centonze, I. G. Rapposelli, G. Giordano, F. De Vita, L. Stuppia, A. Avallone, M. Ratti, C. Paratore, L. G. Forti, G. Orsi, M. M. Valente, M. Gaule, M. Macchini, P. Carrera, S. Calzavara, M. Simbolo, D. Melisi, F. De Braud, L. Salvatore, S. De Lorenzo, C. Chiarazzo, M. Falconi, S. Cascinu, M. Milella, M. Reni, Peretti, U, Cavaliere, A, Niger, M, Tortora, G, Di Marco, M C, Rodriquenz, M G, Centonze, F, Rapposelli, I G, Giordano, G, De Vita, F, Stuppia, L, Avallone, A, Ratti, M, Paratore, C, Forti, L G, Orsi, G, Valente, M M, Gaule, M, Macchini, M, Carrera, P, Calzavara, S, Simbolo, M, Melisi, D, De Braud, F, Salvatore, L, De Lorenzo, S, Chiarazzo, C, Falconi, M, Cascinu, S, Milella, M, Reni, M, Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Di Marco, M. C., Rodriquenz, M. G., Centonze, F., Rapposelli, I. G., Giordano, G., De Vita, F., Stuppia, L., Avallone, A., Ratti, M., Paratore, C., Forti, L. G., Orsi, G., Valente, M. M., Gaule, M., Macchini, M., Carrera, P., Calzavara, S., Simbolo, M., Melisi, D., De Braud, F., Salvatore, L., De Lorenzo, S., Chiarazzo, C., Falconi, M., Cascinu, S., Milella, M., and Reni, M.

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adenocarcinoma, familial cancer, Prostate cancer, Pancreatic cancer, Internal medicine, Epidemiology, Medicine, Humans, Family history, Germ-Line Mutation, Aged, Original Research, pancreatic cancer genetics, Aged, 80 and over, BRCA2 Protein, business.industry, BRCA1 Protein, Incidence (epidemiology), Middle Aged, pancreatic cancer genetic, medicine.disease, germline BRCA, epidemiology, pancreatic cancer genetics, familial cancer, Pancreatic Neoplasms, Exact test, Oncology, Italy, germline BRCA, Cohort, Female, epidemiology, business, Human
Abstract

Objective Germline BRCA1-2 pathogenic variants (gBRCApv) increase the risk of pancreatic cancer and predict for response to platinating agents and poly(ADP-ribose) polymerase inhibitors. Data on worldwide gBRCApv incidence among pancreatic ductal adenocarcinoma (PDAC) patients are sparse and describe a remarkable geographic heterogeneity. The aim of this study is to analyze the epidemiology of gBRCApv in Italian patients. Materials and methods Patients of any age with pancreatic adenocarcinoma, screened within 3 months from diagnosis for gBRCApv in Italian oncologic centers systematically performing tests without any selection. For the purposes of our analysis, breast, ovarian, pancreas, and prostate cancer in a patient's family history was considered as potentially BRCA-associated. Patients or disease characteristics were examined using the χ2 test or Fisher's exact test for qualitative variables and the Student's t-test or Mann–Whitney test for continuous variables, as appropriate. Results Between June 2015 and May 2020, 939 patients were tested by 14 Italian centers; 492 (52%) males, median age 62 years (range 28-87), 569 (61%) metastatic, 273 (29%) with a family history of potentially BRCA-associated cancers. gBRCA1-2pv were found in 76 patients (8.1%; 9.1% in metastatic; 6.4% in non-metastatic). The gBRCA2/gBRCA1 ratio was 5.4 : 1. Patients with gBRCApv were younger compared with wild-type (59 versus 62 years, P = 0.01). The gBRCApv rate was 17.1% among patients 70 years old (none out of 94 patients >73 years old). gBRCApv frequency in 845 patients, Highlights • This is the largest case series of incident PDAC patients screened for germline BRCA1-2 pathologic variants (gBRCApv). • The incidence of gBRCA1-2pv was 8.1% in the whole population; 9.1% in metastatic patients; 6.4% in non-metastatic patients. • No gBRCA1-2pv was observed over the age of 73. • These data suggest screening all PDAC patients

Published
2020

8. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

Author

S. Ochsenreither, W.M. Fiedler, G.D. Conte, M. Macchini, I. Matos, B. Habel, I. Ahrens-Fath, F. Raspagliesi, D. Lorusso, U. Keilholz, C. Rolling, M. Kebenko, K.F. Klinghammer, O. Saavedra, H. Baumeister, A. Zurlo, E. Garralda, Institut Català de la Salut, [Ochsenreither S] Charité Comprehensive Cancer Center, Berlin, Germany. Charité, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany. German Cancer Consortium (DKTK), Berlin, Germany. [Fiedler WM] University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany. [Conte GD, Macchini M] Fondazione IRCCS San Raffaele Hospital, Milan, Italy. [Matos I, Saavedra O, Garralda E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Habel B] Glycotope GmbH, Berlin, Germany, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Cancer Research, Lung Neoplasms, Càncer - Tractament, Mucin-1, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Antibodies, Monoclonal, Antineoplastic Agents, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], Anticossos monoclonals - Efectes secundaris, Neoplasms [DISEASES], neoplasias [ENFERMEDADES], ErbB Receptors, Oncology, Carcinoma, Non-Small-Cell Lung, Other subheadings::Other subheadings::/adverse effects [Other subheadings], Humans, Erratum, Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal [CHEMICALS AND DRUGS], Colorectal Neoplasms, aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales [COMPUESTOS QUÍMICOS Y DROGAS]
Abstract

Colorectal cancer; Lung cancer; Monoclonal antibody Cáncer colorrectal; Cáncer de pulmón; Anticuerpo monoclonal Càncer colorectal; Càncer de pulmó; Anticòs monoclonal Background The phase I GATTO study (NCT03360734) explored the feasibility, tolerability and preliminary activity of combining gatipotuzumab, a novel humanized monoclonal antibody binding to the tumor-associated epitope of mucin 1 (TA-MUC1) and an anti-epidermal growth factor receptor (anti-EGFR) antibody in refractory solid tumors. Patients and methods Initially the study enrolled primary phase (PP) patients with EGFR-positive metastatic solid tumors, for whom no standard treatment was available. Patients received gatipotuzumab administered at 1400 mg every 2 weeks, 6 weeks after the start of the glyco-optimized anti-EGFR antibody tomuzotuximab at 1200 mg every 2 weeks. As this regimen was proven safe, enrollment continued in an expansion phase (EP) of patients with refractory metastatic colorectal cancer, non-small-cell lung cancer, head and neck cancer and breast cancer. Tomuzotuximab and gatipotuzumab were given at the same doses and gatipotuzumab treatment started 1 week after the first dose of the anti-EGFR antibody. Additionally, investigators could use a commercial anti-EGFR antibody in place of tomuzotuximab. Results A total of 52 patients were enrolled, 20 in the PP and 32 in the EP. The combined treatment was well tolerated and no dose-limiting toxicity was observed in the whole study, nor related serious adverse event or death. Preliminary activity of the combination was observed, with one and four RECIST partial responses in the PP and EP, all in colorectal cancer patients. The trial was accompanied by a comprehensive translational research program for identification of biomarkers, including soluble TA-MUC1 (sTA-MUC1) in serum. In the EP, patients with baseline sTA-MUC1 levels above the median appeared to have improved progression-free survival and overall survival. Conclusions Combination of a TA-MUC1-targeting antibody and an EGFR-targeting antibody is safe and feasible. Interesting antitumor activity was observed in heavily pretreated patients. Future studies should test this combination together with chemotherapy and explore the potential of sTA-MUC1 as a companion biomarker for further development of the combination. This work was supported by Glycotope GmbH (no grant number).

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results